CCC Project - Atrial Fibrillation

Atrial Fibrillation Clinical Trial

Official title:

Improving Care for Cardiovascular Disease in China: A Collaborative Project of AHA and CSC (CCC Project) - Atrial Fibrillation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02309398
• Other study ID #: CCC-AF-2014
• Status: Completed
• Start date: January 2015
• Est. completion date: December 2020

Study information

• Verified date: January 2021
• Source: Beijing Institute of Heart, Lung and Blood Vessel Diseases
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to develop and implement quality improvement programs for the treatment of atrial fibrillation (AF) in China based on the successful experience of the AHA-Get with the Guidelines program. This program will use data collection, analysis, feedback, and process improvement to extend the use of evidence-based guidelines throughout the healthcare system and improve patient care of atrial fibrillation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 67028
• Est. completion date: December 2020
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Hospitalized patients with discharge diagnosis as atrial fibrillation in 150 tertiary and 100 secondary hospitals.

Exclusion Criteria:

None

Related Conditions & MeSH terms

• Atrial Fibrillation

Locations

Country	Name	City	State
China	Beijing An Zhen Hospital	Beijing

Sponsors (3)

Lead Sponsor	Collaborator
Beijing Institute of Heart, Lung and Blood Vessel Diseases	American Heart Association, Chinese Society of Cardiology

Country where clinical trial is conducted

China, 

References & Publications (1)

Hao Y, Liu J, Smith SC, Huo Y, Fonarow GC, Ge J, Liu J, Taubert KA, Morgan L, Guo Y, Zhou M, Zhao D, Ma C; CCC-AF Investigators. Rationale and design of the improving Care for Cardiovascular Disease in China (CCC) project: a national registry to improve m — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The overall composite of six performance measures for AF care	Performance measures for AF care including: Proportion of patients received assessment of thromboembolic risk factors; Proportion of patients discharged on warfarin or other anticoagulant drug; Proportion of patients discharged on warfarin who have PT/INR follow-up planned prior to hospital discharge; Proportion of patients with left ventricular systolic dysfunction prescribed an ACEI or ARB at hospital discharge; Proportion of patients with left ventricular systolic dysfunction prescribed a beta blocker at hospital discharge; Proportion of patients with either coronary artery disease, cerebrovascular accident/transient ischemic attack, peripheral vascular disease or diabetes who were prescribed a statin at hospital discharge	Duration of hospital stay, an expected average of 1 week

External Links

•   Website of the study (in Chinese)